Nail toxicity induced by cancer chemotherapy

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 3, 2009, Pages 143-155

  Gilbar, Peter ^a   Hain, Alice ^a   Peereboom Veta Marie, V M ^a  

^a Toowoomba Health Services   (Australia)

Author keywords

Chemotherapy induced; Nail toxicity; Onycholysis; Prevention; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; ASPARAGINASE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; HYDROXYUREA; IDARUBICIN; IMATINIB; IRINOTECAN; IXABEPILONE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABSCESS; ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANAMNESIS; BEAU LINE; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CRYOTHERAPY; DERMATITIS; DESQUAMATION; DRUG MEGADOSE; EDEMA; ERYTHEMA; GERM CELL TUMOR; HORIZONTAL BANDING; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; HYPOMELANOSIS; INGROWN NAIL; KIDNEY CARCINOMA; LACRIMATION DISORDER; LEUKONYCHIA; LOSS OF NAIL PLATE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANONYCHIA; MULTIPLE CYCLE TREATMENT; NAIL COLOR DEFECT; NAIL DISEASE; NAIL DYSCHROMIA; NAIL DYSTROPHY; NAIL FRAGILITY; NAIL HEMORRHAGE; NAIL INFECTION; NAIL LOSS; NAIL PIGMENTATION; NAIL PITTING; NAIL SHEEDING; ONYCHOCLASIS; ONYCHOLYSIS; ONYCHOMADESIS; OVARY CANCER; PAIN; PARONYCHIA; PRIORITY JOURNAL; PSORIASIS; PYOGENIC GRANULOMA; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SKIN APPENDAGE DISEASE; SKIN TOXICITY; SUPPURATION; SWELLING; TESTIS CANCER; XEROSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CRYOTHERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; NAIL DISEASES;

EID: 69849099713     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208100450     Document Type: Review

References (101)

1. Piraccini BM, Iorizzo M., Starace M., Tosti A. Drug-induced nail diseases. Dermatol Clin 2006; 24: 387-91.
2. Piraccini BM, Tosti A. Drug-induced nail disorders. Incidence, management and prognosis. Drug Saf 1999; 21: 187-201.
3. Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin 2007; 25: 215-21.
4. Hinds G., Thomas VD Malignancy and cancer treatment-related hair and nail changes. Dermatol Clin 2008; 26: 59-68.
5. Tosti A, Iorizzo M, Piraccini BM, Starace M. The nail in systemic diseases. Dermatol Clin 2006; 24: 341-7
6. Piraccini BM, Iorizzo M, Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol 2003; 4: 31-7.
7. Haneke E. Surgical anatomy of the nail apparatus. Dermatol Clin 2006; 24: 291-6.
8. Vassallo C., Brazzelli V., Ardigo M., Borroni G. Nail changes secondary to hematologic conditions. Haematologica 2001; 86: 334-6.
9. Uyttendaele H., Geyer A., Scher RK Drugs and nails. J Eur Acad Dermat Venereol 2004; 18: 124-5.
10. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0. Rockville, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. 3rd September 2006.
11. Bagic A., Lupu V., Kessler CM, Tornatore C. Iatrogenic arsenic induced Mees' lines. Postgrad Med 2006; 82: 515.
12. Vogelzang NJ, Bosl GJ, Johnson K., Kennedy BJ Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288-92.
13. Miller RW Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol 1984; 120: 963-4.
14. Susser WS, Whitaker-Worth DL, Grant-Kels JM Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367-98.
15. Chen GY, Chen YH, Hsu MML, Tsao CJ, Chen WC Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001; 145: 520-1.
16. Maino KL, Norwood C., Stashower ME Onycholysis with the appearance of a "sunset" secondary to capecitabine. Cutis 2003; 72: 234-6.
17. Munoz A., Barcelo R., Rubio I., Mane JM, Ferreiro J., Lopez-Vivanco G. Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer. J Natl Cancer Inst 2003; 16: 1252-3.
18. Fox LP Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007; 56: 460-5.
19. Busam KJ, Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern AC Cutaneous side-effects in cancer patients treated with antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 44: 1169-76.
20. Boucher KW, Davidson K., Mirakhur B., Goldberg J., Heymann WR Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 47: 632-3.
21. Monti M., Mancini LL, Ferrari B., Rahal D., Santoro A. Complications of therapy and a diagnostic dilemma case, case 2: Cutaneous toxicity induced by cetuximab. J Clin Oncol 2003; 21: 4651-3.
22. Harrison BM, Wood CBS. Cyclophosphamide and pigmentation. Br Med J 1972; 2: 352.
23. Shah PC, Rao KRP, Patel AR Cyclophosphamide-induced nail pigmentation. Lancet 1975; 2: 548-9.
24. Shah PC, Rao KRP, Patel AR Cyclophosphamide induced nail pigmentation. Br J Dermatol 1978; 98: 675-80.
25. Adam BA Cyclophosphamide nail pigmentation. Sing Med J 1981; 22: 35-7.
26. Srikanth M., Van Veen J., Raithatha A., Reilly JT Cyclophosphamide-induced nail pigmentation. Br J Haematol 2002; 117: 2.
27. Dave S., Thappa DM Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dermatol Online J 2003; 9: 14.
28. deMartinas M., Hendricks A., Stoltzner G. Nail pigmentation with daunorubicin therapy. Ann Intern Med 1978; 89: 516-7.
29. Shelly W., Bennett HG Transverse leukonychia (Mee's lines) due to daunorubicin chemotherapy. Pediatr Dermatol 1997; 14: 144-5.
30. Minisini AM, Tosti A., Sobrero AF et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003; 14: 333-7.
31. Llombart-Cussac A., Pivot X., Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Arch Dermatol 1997; 133: 1466-7.
32. Jacob CI, Patten SF Nail bed dyschromia secondary to docetaxel therapy. Arch Dermatol 1998; 134: 1167-8.
33. Obermair A., Binder M., Barrada M., Bancher-Todesca D., Asseryanis E., Kubista E. Onycholysis in patients treated with docetaxel. Ann Oncol 1998; 9: 230-1.
34. Correia O., Azevedo C., Pinto Ferreira E., Braga Cruz F., Polonia J. Nail changes secondary to docetaxel (Taxotere). Dermatol 1999; 198: 288-90.
35. Vanhooteghem O., Richert B., Vindevoghel A., Vandenbossche L., Vandeveire A., de la Brassinine M. Subungual abscess: A new ungual side-effect related to docetaxel therapy. Br J Dermatol 2000; 143: 462-4.
36. Pavithran K., Doval DC Nail changes due to docetaxel. Br J Dermatol 2002; 146: 709-10.
37. Abou Mourad Y., MattaΜallem M., Shamseddine A. Nail toxicity related to taxanes. Dermatol Online J 2003; 9: 15.
38. Chen GY, Chang TW, Chen WC Exudative hypoychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: Report of three cases. Br J Dermatol 2003; 148: 1071-3.
39. Mortimer NJ, Mills J. Beau's lines. New Engl J Med 2004; 351: 17.
40. Alexandrescu DT, Vailant J., Wiernik PH Trastuzumab/docetaxel-induced nail dystrophy. Int J Dermatol 2006; 45: 1334-6.
41. Wasner G., Hilpert F., Baron R., Pfisterer J. Nail changes secondary to docetaxel. Lancet 2001; 357: 910.
42. Nicolopoulos J., Howard A. Docetaxel-induced nail dystrophy. Australas J Dermatol 2002; 43: 293-6.
43. Wasner G., Hilpert F., Schattschneider J., Binder A., Pfisterer J., Baron R. Docetaxel-induced nail changes - a neurogenic mechanism: A case report. J Neuro Oncol 2002; 58: 167-74.
44. Roh MR, Cho JY, Lew W. Docetaxel-induced onycholysis: The role of subungual hemorrhage and suppuration. Yonsei Med J 2007; 48: 124-6.
45. Hong J., Park SH, Choi SJ et al. Nail toxicity after treatment with docetaxel: A prospective analysis in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2007; 37: 424-8.
46. Winther D., Saunte DM, Knap M., Haahr V., Jensen AB Nail changes due to docetaxel: A neglected side effect and nuisance for the patient. Support Care Cancer 2007; 15: 1191-7.
47. Valero V., Holmes FA, Walters RS et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
48. Engels FK, Verweij J. Docetaxel administration schedule: From fever to tears? A review of randomised studies. Eur J Cancer 2005; 41: 1117-26.
49. Priestman TJ, James KW Adriamycin and longitudinal pigmented banding of fingernails. Lancet 1975; 1: 1337.
50. Curran CF Onycholysis in doxorubicin-treated patients. Arch Dermatol 1990; 126: 1244.
51. Bird BR, Elfiki T., Tucker O., O'Reilly S. Unilateral nail changes secondary to Adriamycin: The protective effect of brachial plexopathy. Ann Oncol 2006; 17: 527.
52. 2) given as 200 and 150 mg single doses from days 1-10 every 3 weeks. Gynecol Oncol 1995; 57: 436.
53. Chen GY, Chen W., Huang WT Single transverse apparent leukonychia caused by 5-fluorouracil plus leucovorin. Dermatol 2003; 207: 86-7.
54. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small cell lung cancer. J Clin Oncol 2004; 22: 4646-7.
55. Vomvouras S., Pakula AS, Shaw JM Multiple pigmented nail bands during hypdroxyurea therapy: An uncommon finding. J Am Acad Dermatol 1991; 24: 1016-7.
56. Kwong YL Hydroxyurea-induced nail pigmentation. J Am Acad Dermatol 1996; 35: 275-6.
57. Cakir B., Sucak G., Haznedar R. Longitudinal pigmented nail bands during hydroxyurea therapy. Int J Dermatol 1997; 36: 236-7.
58. Hernandez-Martin A., Ros-Forteza S., de Unamuno P. Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. J Am Acad Dermatol 1999; 40: 333-4.
59. Las Heras G., Piera JJ Nail changes after chemotherapy. Haematologica 1998; 83: 748.
60. O'Branski EE, Ware RE, Prose NS, Kinney TR Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol 2001; 44: 859-61.
61. Aste N., Fumo G., Contu F., Aste N., Biggio P. Nail pigmentation caused by hydroxyurea: Report of 9 cases. J Am Acad Dermatol 2002; 47: 146-7.
62. Kumar B., Saraswat A., Kaur I. Mucocutaneous adverse effects of hydroxyurea: A prospective study of 30 psoriasis patients. Clin Exp Dermatol 2002; 27: 8-13.
63. Oh ST, Lee DW, Lee JY, Cho BK Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption. J Am Acad Dermatol 2003; 49: 339-41.
64. Issaivanan M., Mitu PS, Chakrabarti M., Khairkar P. Cutaneous manifestations of hydroxyurea in childhood: Case report and review. Pediatr Dermatol 2004; 00: 124-127.
65. Zargari O., Kimyai-Asadi A., Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia. Pediatr Dermatol 2004; 21: 633-5.
66. Teo RYL, Tan E. A case of hydroxyurea-induced transverse melanonychia. Int J Dermatol 2006; 45: 1329-30.
67. Borecky DJ, Stephenson JJ, Keeling JH, Vukelja SJ Idarubicin-induced pigmentary changes of the nails. Cutis 1997; 59: 203-4.
68. Deliliers GL, Monni P. Nail transverse white bands induced by antileukemic chemotherapy. Haematologica 2001; 86: 333.
69. Prabhash K., Biswas G., Prasad N., Karant N. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Ind J Dermatol Venereol Leprol 2006; 72: 63.
70. Deguchi N., Kawamura T., Shimizu A. et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br J Dermatol 2006; 154: 1216-8.
71. Alimonti A., Nardoni C., Papaldo P. et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res 2005; 25: 3531-2.
72. Wantzin GL, Thomsen K. Acute paronychia after high-dose methotrexate therapy. Arch Dermatol 1983; 119: 623-4.
73. Chang JC Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Arch Dermatol 1987; 123: 990-2.
74. Malka N., Reichert S., Trechot P., Barbaud A., Schmutz JL Yellow nail pigmentation due to methotrexate. Dermatol 1998; 197: 276.
75. Speechy-Dick ME, Owen ERTC. Mitozantrone-induced onycholysis. Lancet 1988; 331: 113.
76. Mitchell PLR, Harvey VJ Mitozantrone-induced onycholysis. Eur J Cancer 1992; 28: 243-4.
77. Creamer JD, Mortimer PS, Powles TJ Mitozantrone-induced onycholysis: A series of five cases. Clin Exp Dermatol 1995; 20: 459-61.
78. Makris A., Mortimer P., Powles TJ Chemotherapy-induced onycholysis. Eur J Cancer 1996; 32A: 374-5.
79. Freiman A., Bouganim N., O'Brien EA Mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma. J Drugs Dermatol 2005; 4: 490-1.
80. Link Jr CJ, Sarosy GA, Kohn EC, Christian MC, Davis P. Cutaneous manifestations of taxol® therapy. Invest New Drugs 1995; 13: 261-3.
81. Lehoczky O., Pulay T. Transverse leukonychia secondary to paclitaxel-carboplatin chemotherapy in a patient with ovarian cancer. J Obstet Gynae 2002; 22: 694.
82. De Giorgi U., Rosti G., Monti M., Frassineti GL, Marangolo M. Onycholysis secondary to multiple paclitaxel 1-hour infusions: Possible role fore its venicle (Cremophor EL). Ann Oncol 2003; 14: 1588-9.
83. Luftner D., Flath B., Akrivakis C. et al. Dose-intensified weekly paclitaxel induces multiple nail disorders. Ann Oncol 1998; 9: 1139-41.
84. Flory SM, Solimando Jr DA, Webster GF, Dunton CJ, Neufeld JM, Haffey MB Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 1999; 33: 584-6.
85. Almagro M., del Pozo J., Garcia J., Vasquez A., Fonseca E. Nail alterations secondary to paclitaxel therapy. Eur J Dermatol 2000; 10: 146-7.
86. Hussain S., Anderson DN, Salvatti ME, Adamson B., McManus M., Braverman AS Onycholysis as a complication of systemic chemotherapy. Cancer 88: 2367-71.
87. Spazzapan S., Crivellari D., Lombardi D. et al. Nail toxicity related to weekly taxanes: An important issue requiring a change in common toxicity criteria grading? J Clin Oncol 2002; 20: 4404-5.
88. Albares MP, Belinchon I., Pascual JC, Vergara G., Blanes M., Betlloch I. Subungual abcesses secondary to paclitaxel. Dermatot Online J 2003; 9: 16.
89. Mackay-Wiggan J., Nair KG, Halasz CLG. Onycholysis associated with paclitaxel. Cutis 2003; 71: 229-32.
90. Ghetti E., Piraccini BM, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 2003; 17: 459-60.
91. Dasanu CA, Wiernik PH, Vaillant J., Alexandrescu DT A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. SKINmed 2007; 6: 95-6.
92. Robert C., Faivre S., Raymond E., Armand JP, Escudier B. Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors?. Ann Intern Med 2005; 143: 313-4.
93. Chen GY, Chao SC, Chen W. Black lunula caused by tegafur. Acta Derm Venereol 2004; 84: 238-9.
94. Baykal Y., Baykal C., Ozer S., Tulunay G. Topotecan induced nail pigmentation. J Dermatol 2004; 31: 951-2.
95. Chapman S., Cohen PR Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 1997; 90: 395-8.
96. Lang K., Groeger M., Neumann NJ, Ruzicka T., Fritsch C. Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's disease. J Eur Acad Dermatol Venereol 2002; 16: 162-3.
97. Dasanu CA, Vaillant JG, Alexandrescu DT Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, Adriamycin, dexamethasone therapy for multiple myeloma. Dermatol Online J 2006; 12: 10.
98. Chen W., Yu YS, Liu YH, Sheen JM, Hsiao CC Nail changes with chemotherapy in children. J Eur Acad Dermatol Venereol 2007; 21: 186-90.
99. Yoruk A., Yukselgungor H. Chemotherapy induced transverse leukonychia in children. Int J Dermatol 2003; 42: 468-9.
100. Scotte F., Tourani JM, Banu E. et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424-9.
101. Scotte F., Banu E., Medioni J. et al. Matched case-control phase 2 study to evaluate the use of a frozen ock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008; 112: 1625-31.